How does GSK make money in 2026? The answer begins with its three biopharmaceutical product groups, but the full business model involves drug discovery, clinical trials, regulatory approvals, manufacturing, healthcare reimbursement and product lifecycles. This analysis uses GSK’s 2025 annual report and its latest published 2026 quarterly results to explain the economics behind its sales and profits.
Overview: A Focused Biopharmaceutical Business
GSK is a UK-headquartered biopharmaceutical company that researches, develops, manufactures and commercialises prescription medicines and vaccines. Its business is not a consumer-health conglomerate: the former consumer healthcare business was separated as Haleon in 2022. In 2026 GSK operates through three major product groups: Specialty Medicines, Vaccines and General Medicines. Each serves different patients, customers and healthcare systems, but all rely on scientific evidence, regulatory approval, reliable supply and access to reimbursement.
The 2025 annual report records turnover of £32.667 billion, up 4% at actual exchange rates and 7% at constant exchange rates. Specialty Medicines contributed £13.5 billion, Vaccines £9.2 billion and General Medicines £10.0 billion. Those figures reveal a diversified revenue base, though growth differs materially by category. Specialty Medicines grew 17% at constant currency, Vaccines 2%, while General Medicines declined 1%. The mix matters because products have different patent lives, manufacturing complexity, commercial costs and exposure to generic competition.
The company does not earn revenue simply by inventing medicines. A product must pass preclinical and clinical testing, secure approval, be manufactured to regulated quality standards, reach the appropriate market and be prescribed or purchased. Payments may come through wholesalers, pharmacies, hospitals, government procurement agencies and other healthcare intermediaries. The patient who ultimately uses a product is frequently not the entity that directly pays GSK. This distinction shapes pricing, market access, inventory and receivables.
GSK’s economic engine combines established products that generate current cash with research programmes intended to create future products. Existing sales help fund clinical development, manufacturing capacity and shareholder returns. New approvals can extend the portfolio, but not every candidate succeeds. The model is therefore a portfolio of scientific and commercial risks rather than a simple recurring subscription business. Its long-term performance depends on how efficiently research spending is converted into approved treatments that remain competitive.
Related GSK analysis: Business Model | Business Strategy | SWOT | PESTEL
Problem and Solution: From Unmet Medical Needs to Approved Products
The problems GSK addresses include infectious disease prevention, chronic respiratory illness, HIV, immune-mediated conditions and cancer. Patients and health systems need therapies that improve outcomes, prevent complications or reduce disease burden. A vaccine is economically different from a medicine taken regularly: it may be administered once or periodically to a defined population, while chronic therapies can create repeated demand over many years. The company must understand the clinical need and the purchasing system for each product.
Drug discovery begins with identifying biological targets and testing potential interventions. Successful candidates progress through increasingly demanding studies intended to assess safety, efficacy and appropriate use. Regulatory agencies review evidence before a product can be marketed. Even after approval, manufacturers must monitor safety and maintain compliance. This process requires substantial investment before revenue is certain, and failure can occur late in development after years of spending.
GSK’s 2025 strategic report highlights respiratory, immunology and inflammation, oncology and HIV within Specialty Medicines. It also describes broad vaccine capabilities covering diseases such as shingles, meningitis and respiratory syncytial virus. General Medicines include established respiratory treatments and antibiotics. These are not interchangeable products. Their medical indications, patent positions, pricing frameworks and supply requirements differ, so the commercial model must be analysed at the portfolio level rather than through a single average price.
The solution that creates commercial value is not merely a molecule or vaccine antigen. It is a validated product supported by clinical evidence, regulatory authorisation, scalable production and a distribution system that healthcare providers can trust. Additional value may arise from new indications, improved formulations or broader access to patients. Conversely, a product may lose sales when competitors offer better outcomes, when reimbursement changes or when intellectual-property protection expires. Innovation and lifecycle management therefore operate together.
Related GSK analysis: Business Model | Business Strategy | SWOT | PESTEL
Revenue Model: Specialty Medicines
Specialty Medicines is GSK’s largest product group and the principal recent growth driver. It generated £13.5 billion of turnover in 2025, including approximately £7.7 billion from HIV, £3.8 billion from respiratory, immunology and inflammation, and £2.0 billion from oncology. At constant exchange rates these businesses grew 11%, 18% and 43%, respectively. These figures show that the group’s expansion has increasingly depended on differentiated therapies rather than volume growth in older primary-care medicines.
Specialty products often address diseases where prescribing requires specialist diagnosis or treatment decisions. Revenue depends on eligible patient populations, clinical guidelines, competing therapies, pricing and reimbursement. Successful launches can generate meaningful revenue as physicians gain experience and healthcare systems approve funding. However, the cost of clinical trials, regulatory submissions and specialist commercial support can be substantial. Sales growth should therefore be evaluated against the investment required to obtain it.
GSK’s HIV business operates through ViiV Healthcare, a business with its own ownership arrangements and collaborations. HIV medicines can produce recurring revenue because many patients require sustained treatment, although regimen choice, prevention products, competition and patent protection shape the market. Oncology products may expand through approvals in additional cancer types or treatment settings. Immunology and respiratory products can likewise grow through clinical evidence supporting new patient groups. These pathways make the product lifecycle central to revenue forecasting.
The first nine months of 2026 reinforced the importance of this category. GSK’s third-quarter release reported Specialty Medicines revenue of about £3.9 billion, up 15% at constant currency, including growth in HIV, respiratory, immunology and oncology. A strong quarter does not guarantee that every candidate in the pipeline will succeed. Analysts should monitor approved-product sales, launch trajectories, late-stage trial outcomes and upcoming patent or exclusivity changes to understand whether category growth is durable.
Related GSK analysis: Business Model | Business Strategy | SWOT | PESTEL
Revenue Model: Vaccines
Vaccines generated £9.2 billion of GSK’s 2025 turnover. Major products included Shingrix, a shingles vaccine with approximately £3.6 billion of sales, meningitis vaccines with £1.6 billion and Arexvy, an RSV vaccine with approximately £0.6 billion. Vaccines have a distinctive revenue model: demand is influenced by eligibility recommendations, public-health programmes, age cohorts, vaccination rates, seasonal factors and the timing of government or institutional purchases.
Manufacturing vaccines requires complex biological processes, specialised facilities and rigorous quality control. Capacity cannot always be expanded as quickly as demand, and production disruptions can affect supply. Unlike a consumer subscription, a vaccine course may not produce monthly revenue from the same person. Growth may depend on reaching new eligible populations, expanding geographic access, securing recommendations or launching new products. The cost of prevention programmes is often assessed by public-health agencies and payers.
Shingrix illustrates both the potential and the limits of a major vaccine franchise. It has been an important contributor to GSK’s revenue, but sales can vary with uptake, inventories, competitive conditions and programme timing. In Q3 2026 GSK reported vaccine sales of about £2.6 billion, down 2% at constant currency, with Shingrix down 5% and Arexvy down 24%. Meningitis vaccines grew 12%. These divergent trends demonstrate why aggregate vaccine revenue should not be treated as uniformly predictable.
The vaccine business benefits from scientific expertise, established manufacturing infrastructure and relationships with public-health organisations. Its risks include changing recommendations, competitive launches, supply challenges and lower-than-expected uptake. A strong product can have significant clinical and commercial value, but vaccination is also shaped by affordability, public trust and access. GSK must invest in evidence generation and supply reliability while adapting to local health-system purchasing practices.
Related GSK analysis: Business Model | Business Strategy | SWOT | PESTEL
Revenue Model: General Medicines
General Medicines generated £10.0 billion in 2025, approximately one-third of GSK’s total turnover. The category includes established respiratory treatments, antibiotics and other primary-care medicines. It serves large patient populations and often involves substantial manufacturing volumes. The 2025 strategic report states that General Medicines represent more than 70% of the group’s total medicines and vaccines supply volume, illustrating the contrast between units supplied and revenue contribution.
Trelegy was a major growth product, with approximately £3.0 billion in 2025 sales and 13% constant-currency growth. Other respiratory brands include Anoro, Relvar and Ventolin, while Augmentin is a longstanding antibiotic franchise. These products differ in indications and competitive environments. Some benefit from brand familiarity and clinical evidence, while others face generic or alternative-treatment competition. Their revenue is shaped by prescriptions, formulary inclusion, distribution and healthcare-system pricing.
The overall General Medicines category declined 1% at constant currency in 2025. Growth in Trelegy was offset by reductions elsewhere, including the effect of generic competition. This is a normal but important feature of pharmaceutical economics: products may generate cash for years, yet revenue can decline when exclusivity expires or alternatives gain share. Maintaining a broad portfolio helps smooth some individual-product changes, but does not eliminate structural pressure.
General Medicines also matter strategically because their cash contribution helps fund research and newer products. A mature franchise need not grow rapidly to remain economically useful, provided manufacturing, selling costs and working capital are controlled. However, relying on older products without replacing them would eventually weaken the business. Analysts should examine price, volume, generic erosion and margin rather than assuming that a stable sales figure means the underlying portfolio is unchanged.
Related GSK analysis: Business Model | Business Strategy | SWOT | PESTEL
How GSK Makes Profit: Research, Manufacturing and Distribution
GSK’s 2025 total operating profit was £7.932 billion, while core operating profit was £9.783 billion. The difference matters because core is a non-IFRS performance measure that excludes specified items under the company’s definitions. The reported total operating margin was 24.3%, compared with a core operating margin of 29.9%. It would be misleading to present the higher core margin as the statutory profit margin without explaining the adjustments. Both figures provide information, but they answer different questions.
Research and development is a major investment category. GSK’s 2025 report describes approximately £7.5 billion of R&D investment, reflecting the scale of work required to discover, test and register medicines and vaccines. Some programmes will not reach the market. Even successful programmes may require additional trials for new indications or formulations. The economic return from R&D is therefore realised over many years and depends on a portfolio of uncertain outcomes.
Manufacturing and distribution add another layer of cost. GSK reported 33 manufacturing sites and approximately 18,000 direct suppliers at the end of 2025. Medicines and vaccines must be produced consistently, packaged correctly and distributed under appropriate conditions. Quality failures, shortages or regulatory findings can disrupt supply and lead to remediation expense. Supply-chain resilience is therefore not merely an operational issue; it protects revenue and patient access.
Cash flow is the final test of reported profitability. In 2025 GSK generated £8.943 billion of cash from operations and approximately £4.0 billion of free cash flow. Free cash flow is lower because the business must fund capital spending and other cash requirements. Working capital, legal payments, acquisitions, dividends and debt movements can further affect liquidity. A sound business-model assessment considers cash generation alongside revenue, total operating profit and core metrics.
Related GSK analysis: Business Model | Business Strategy | SWOT | PESTEL
Business Model Outlook in 2026 and Beyond
GSK’s model increasingly relies on replacing older products with differentiated specialty medicines and vaccines while retaining the financial contribution of established therapies. The company has communicated a long-term ambition for more than £40 billion in sales by 2031. This is a management outlook rather than a guaranteed outcome. It depends on launch execution, research success, reimbursement, competition and the performance of existing franchises. A single strong year cannot remove the uncertainty inherent in drug development.
The company’s Q3 2026 results showed total quarterly sales of approximately £8.9 billion, up 5% at constant exchange rates. Specialty Medicines performed strongly, while Vaccines declined. GSK maintained full-year guidance for turnover growth of 3% to 5% at constant currency and core operating profit growth of 7% to 9%. Those figures should be read as management expectations subject to risks, not as a substitute for actual full-year results.
An additional challenge is balancing investment and shareholder distributions. Acquisitions and partnerships can bring new assets into the pipeline but may require significant upfront payments and subsequent development spending. Dividends and buybacks return cash to investors, yet reduce funds available for other purposes. The optimal allocation depends on expected scientific returns, balance-sheet resilience and the timing of future cash needs. The financial case for each transaction should be considered separately.
In summary, GSK makes money by developing and selling regulated medicines and vaccines through healthcare systems around the world. Specialty Medicines currently provide the strongest growth, Vaccines offer substantial but variable revenue, and General Medicines provide scale and established cash-generating products. The essential questions are whether research investment produces successful new therapies, whether manufacturing and market access support profitable launches, and whether cash flow remains strong as the portfolio evolves.
Related GSK analysis: Business Model | Business Strategy | SWOT | PESTEL
Why Intellectual Property and Market Access Matter
Patent rights and regulatory exclusivities can provide a period in which an innovative medicine faces less direct generic competition. The duration and strength of protection vary by country and product, and litigation can affect when competitors enter. Even with valid patents, commercial success is not automatic: health systems may restrict reimbursement, physicians may prefer alternatives and clinical guidelines may change. When exclusivity ends, lower-priced competitors can put pressure on sales. GSK therefore needs a continuous pipeline of new medicines and lifecycle improvements to replace revenue that may decline over time.
Market access is equally important. The company may negotiate with national health systems, insurers, hospitals and other payers, often under rules that differ substantially across countries. List prices do not necessarily equal realised revenue because rebates, discounts and other arrangements can apply. A medicine with strong clinical evidence may still see slow uptake if reimbursement is limited. These commercial realities explain why regulatory approval is a milestone rather than the final step in creating a profitable product.
Reading the 2026 Results Responsibly
GSK reports both actual-exchange-rate and constant-exchange-rate growth. Constant-currency measures help isolate trading trends from movements in sterling, but actual exchange rates determine the amounts consolidated in the financial statements. Analysts should use both perspectives. Likewise, core operating profit is designed to explain management’s view of underlying performance, while total operating profit reflects statutory reporting. Restructuring charges, impairments and legal items may cause material differences between the two.
The 2026 quarterly results highlight why product mix is more informative than group revenue alone. Strong Specialty Medicines growth can coexist with weaker vaccine demand, while General Medicines may remain relatively stable. A robust forecast should therefore build from the three product groups and major brands rather than apply a single growth rate across the entire business. It should also consider clinical-trial outcomes, generic entry, manufacturing reliability and payer decisions. These variables ultimately determine whether GSK can convert scientific innovation into durable earnings and cash flow.
Additional perspective: Pharmaceutical revenues are also sensitive to the timing of shipments and wholesaler inventories, not only the number of patients receiving treatment in a given quarter. Healthcare purchasing cycles, vaccination campaigns and tender awards can shift revenue between periods. This is why comparisons should use several years of data and product-level trends. GSK’s financial disclosures help separate operational performance from currency movements, legal expenses and other adjustments. The resulting picture is more useful than judging the entire company by a single product launch or one quarter of sales.
Sources: GSK Annual Report 2025; GSK Q3 2026 results.
